scholarly journals Risk of second breast cancer events with chronic opioid use in breast cancer survivors

2019 ◽  
Vol 28 (5) ◽  
pp. 740-753 ◽  
Author(s):  
Denise M. Boudreau ◽  
Lu Chen ◽  
Onchee Yu ◽  
Erin J. Aiello Bowles ◽  
Jessica Chubak

2019 ◽  
Vol 15 (9) ◽  
pp. e777-e786 ◽  
Author(s):  
Raj Desai ◽  
Fabian Camacho ◽  
Xi Tan ◽  
Virginia LeBaron ◽  
Leslie Blackhall ◽  
...  

PURPOSE: Prolonged opioid use is common and associated with lower survival rates in breast cancer survivors. We explored whether opioid use in elderly breast cancer survivors using adjuvant endocrine therapy (AET) regimens was affected by the prevalence of mental health comorbidity and, in turn, how this affected survival in this population. METHODS: This retrospective study analyzed 2006 to 2012 SEER-Medicare data sets and followed patients for at least 2 years from the index date, defined as the first date they filled an AET prescription. The study included adult women with incident, primary, hormone receptor–positive, stage I to III breast cancer. They were also first-time AET users and fee-for-service Medicare enrollees continuously enrolled in Medicare Parts A, B, and D. We measured whether patients with a clinical diagnosis of a mental health comorbid condition used opioids after the initiation of AET and their survival at the end of the study period. RESULTS: A total of 10,452 breast cancer survivors who began AET treatments were identified, among whom the most commonly diagnosed mental health comorbidities were depression (n = 554) and anxiety (n = 246). Using a propensity score risk adjustment model, we found that opioid use was significantly higher in women with a mental health comorbidity (odds ratio,1.33; 95% CI, 1.06 to 1.68). In addition, mental health comorbidity was associated with a significantly increased hazard of mortality in this population (hazard ratio, 1.49; 95% CI, 1.02 to 2.18). CONCLUSION: The presence of mental health comorbidity in breast cancer survivors significantly increases the risk of opioid use and mortality, which highlights the need for better management of comorbid mental health conditions.



2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 12098-12098
Author(s):  
Aaron N Winn ◽  
Devon Check ◽  
Nicole Fergestrom ◽  
Joan Marie Neuner ◽  
Andrew Roberts

12098 Background: Older adults and cancer survivors are underrepresented in the literature underpinning recent opioid prescribing guidelines. As prevention of unnecessary persistent opioid use and inadvertent opioid-related harms gains importance in clinical practice, it is necessary to fully capture the risks of opioid related adverse events among patients with cancer pain. The objective of this study was to determine the association between opioid use after cancer diagnosis and comprehensive opioid-related adverse events among older adult breast cancer survivors. Methods: We conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results tumor registry data linked with Medicare administrative claims data from 2007-2016 of women with newly diagnosed non-metastatic breast cancer. The study observation period was the year following a patient’s end of active cancer treatment. The primary exposure was a daily measure of opioid exposure based on Part D prescription claims. The primary outcomes were daily indicators of all-cause hospitalization, substance use event and a composite of other opioid-related adverse events (infections, gastrointestinal events, falls/fractures, cardiovascular events) and each component of the composite adverse event. We estimated the association of current opioid use and the immediate risk of an outcome event the following day using modified Poisson generalized estimating equation models. We adjusted for patient demographics, cancer characteristics and cancer treatments received. Results: We found that opioid exposure more than doubled the immediate risk of all-cause hospitalization (aRR = 2.77; 95%CI = 2.57, 2.99; p < 0.001) and having a composite adverse event (aRR = 2.50; 95%CI = 2.18, 2.87; p < 0.001) and dramatically increases the immediate risk of a substance use event (aRR = 14.26; 95%CI = 7.11, 28.59; p < 0.001). We find consistent results when looking at individual components of the composite adverse event measure. Conclusions: Older adult breast cancer survivors with continued prescription opioid use in the year after completing active cancer treatment experienced an immediate increased risk of all-cause hospitalization, substance use events, and myriad opioid-related adverse effects.



2018 ◽  
Vol 21 ◽  
pp. S154-S155
Author(s):  
R.A. Desai ◽  
F. Camacho ◽  
X. Tan ◽  
V. LeBaron ◽  
L. Blackhall ◽  
...  


The Breast ◽  
2019 ◽  
Vol 45 ◽  
pp. 70-74
Author(s):  
A.M.W.M. Aarts ◽  
S.W. Duffy ◽  
S.M.E. Geurts ◽  
D.P. Vulkan ◽  
N. Houssami ◽  
...  


2010 ◽  
Vol 43 (7) ◽  
pp. 17
Author(s):  
SARA FREEMAN




2013 ◽  
Author(s):  
Laura Q. Rogers ◽  
R. Trammell ◽  
S. Vicari ◽  
P. Hopkins-Price ◽  
A. Spenner ◽  
...  


2013 ◽  
Author(s):  
Shannon L. Mihalko ◽  
Samantha E. Yocke ◽  
Greg Russell ◽  
Marissa Howard-McNatt ◽  
Edward A. Levine


2010 ◽  
Author(s):  
Julianne Oktay ◽  
Melissa Bellin ◽  
Susan Scarvalone ◽  
Susan Appling ◽  
Ryan MacDonald ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document